Aria Reports Positive Preclinical Data for 2 New IPF Treatments

Aria Reports Positive Preclinical Data for 2 New IPF Treatments

304425

Aria Reports Positive Preclinical Data for 2 New IPF Treatments

TXR-1002 and TXR-1007, two new therapeutic candidates for idiopathic pulmonary fibrosis (IPF) from Aria Pharmaceuticals, demonstrated significant efficacy at reducing tissue scarring and good tolerability in a mouse model of the disease. Moreover, Aria said, the new artificial intelligence approach its researchers used in the lab to identify and test these compounds took just three months in total — “significantly faster than traditional drug discovery processes,” the company said in a press release. Aria presented its…

You must be logged in to read/download the full post.